Peter G. writes, "You should reconsider your negative articles on Amarin ( AMRN), it might have a secondary benefit other than for the heart. Someone suggested it might grow hair on bald men. Now that would be a big market for some, don't you think????" I thought insults about male baldness lost their sting 20 years ago? Seriously, look around. The only person bothered by being bald today is Donald Trump.
Sticking with Amarin, Thomas P. asks, "What happened to the Adam Feuerstein who called Vascepa 'best in class' and referred to its clinical results as 'spectacular'? Your recent parsings of supposed subtle changes in statements of the company regarding NCE status amount to a distinction without a difference. I call to your attention last year's Shareholder Letter. Zakrzewski stated then quite clearly that he thought the company had good arguments, but that he could not guarantee that the FDA would accept them. Pretty much what is being said right now. And what, pray tell, would be so awful about going it alone? It's not black and white, after all. Talks would likely continue, and perhaps intensify after the sNDA Anchor filing expected early next year, which could expand the market opportunity tenfold."
One more Amarin email, this one from Trez45, "What will you do if Amarin announces a buy out next month timed to its third-quarter conference call?" I will congratulate Amarin longs, assuming the acquisition price is at a significant premium to the company's recent $15-per-share high. I will admit my recent bearishness was overdone. I will also be incredibly surprised because I don't believe Amarin is going to announce a buyout on its third-quarter conference call. Amarin's third-quarter earnings release and call are important. Vascepa was approved in late July but the company has still not made public the drug's commercial launch plans. Amarin can't delay forever because investors are already growing impatient. If Amarin has a partner lined up to help launch Vascepa, then management needs to disclose. If not, then step up and admit that they're moving ahead on their own.
Anthony M. writes, "Dear Mr. Feuerstein, I have read your article and also the Star Scientific ( STSI)/Roskamp press release. I can't understand what your gripe is about. Has Star upset you in some way? There are millions of diabetes sufferers in the world and in the event it proves, which Star does not claim at the moment, that 25% of them may be helped with Anatabloc, either to get off entirely or reduce the metformin they take then this is a giant leap and is to be welcomed." Wouldn't it be great if a dietary supplement sold at GNC stores could somehow cure diabetes? Too bad it will never happen.
@biostockfly asks, "You don't like this drug from $KERX either? Thought data looked good?" I'm assuming you're referring to the phosphate binder Zerenex since that's the only drug left in Keryx Pharmaceuticals' ( KERX) late-stage pipeline following the perifosine blowup. I'm willing to assume the long-term safety study of Zerenex comes back clean when results are reported later this quarter. You can probably trade around this catalyst if that's your thing. But once the buzz dies down, Keryx goes dark as it waits a year for Zerenex to be filed with FDA and reviewed. In that downtime, Keryx will raise money. And even if Zerenex is approved, the drug will not sell. Dialysis providers operating under the cost constrictions of a "bundled" Medicare reimbursement system will flock to cheaper, generic phosphate binders. Zerenex will be left in the cold. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.